Skip to content

Study · Case report or series · n = 5 · 2024

4 results

Outcomes of Semaglutide Use in Achieving Target Body Mass Index Before Renal Transplant in Five End-Stage Renal Disease Patients: A Case Series.

Al-Saad N, Suhagiya GH, Shah BUD, Malik J, Zaidi SMJ

Cureus15 Oct 2024Cited by 1 (Europe PMC)

PMID39553100 (opens in a new tab)PMCIDPMC11563773 (opens in a new tab)DOI10.7759/cureus.71511 (opens in a new tab)PepBankPUB-39553100
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Obesity is a significant barrier to renal transplantation due to associated surgical risks and postoperative complications. This case series presents five cases of obese patients with end-stage renal disease (ESRD) who successfully achieved substantial weight loss using semaglutide, a glucagon-like peptide (GLP) type-1 receptor agonist, thereby becoming eligible for transplantation. Each patient experienced significant weight reduction, ranging from 11.7% to 14.8% of their baseline weight, with minimal side effects. Semaglutide was well-tolerated, and careful monitoring prevented complications such as fluid overload. These cases highlight the potential of semaglutide as an effective and safe adjunct for weight loss in ESRD patients, offering a viable alternative to lifestyle interventions and bariatric surgery. The findings suggest that semaglutide could broaden the pool of eligible transplant candidates and improve patient outcomes by using semaglutide as a weight loss therapy. Further research is warranted to explore its long-term effects on transplant outcomes and to develop guidelines for its use in clinical practice.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In five obese adults with end-stage renal disease, each patient lost 11.7% to 14.8% of baseline weight on semaglutide.

    In plain wordsIn five obese adults with end-stage kidney disease, each patient lost 11.7% to 14.8% of their weight on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction
    Study

    n = 5

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight reduction
    11.7 to 14.8%
    five patients

    Source sentences

    Summary
    Each patient experienced significant weight reduction, ranging from 11.7% to 14.8% of their baseline weight
    1 context sentence
    Summary · context
    This case series presents five cases of obese patients with end-stage renal disease (ESRD) who successfully achieved substantial weight loss using semaglutide, a glucagon-like peptide (GLP) type-1 receptor agonist, thereby becoming eligible for transplantation.
  2. 02HumanCase report or seriesSafety outcome

    In five obese adults with end-stage renal disease, semaglutide caused minimal side effects.

    In plain wordsIn five obese adults with end-stage kidney disease, semaglutide caused few side effects.

    Peptide
    Semaglutide
    Outcome
    No significant changeSide effects
    Study

    n = 5

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with minimal side effects.
    1 context sentence
    Summary · context
    This case series presents five cases of obese patients with end-stage renal disease (ESRD) who successfully achieved substantial weight loss using semaglutide, a glucagon-like peptide (GLP) type-1 receptor agonist, thereby becoming eligible for transplantation.
  3. 03HumanCase report or seriesSafety outcome

    In five obese adults with end-stage renal disease, careful monitoring prevented complications such as fluid overload during semaglutide treatment.

    In plain wordsIn five obese adults with end-stage kidney disease, careful monitoring prevented problems such as fluid overload during semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    No significant changeComplications such as fluid overload
    Study

    n = 5

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    careful monitoring prevented complications such as fluid overload.
    1 context sentence
    Summary · context
    This case series presents five cases of obese patients with end-stage renal disease (ESRD) who successfully achieved substantial weight loss using semaglutide, a glucagon-like peptide (GLP) type-1 receptor agonist, thereby becoming eligible for transplantation.
  4. 04HumanCase report or seriesEfficacy outcome

    In five obese adults with end-stage renal disease, semaglutide weight loss made the patients eligible for transplantation.

    In plain wordsIn five obese adults with end-stage kidney disease, weight loss on semaglutide made them eligible for a kidney transplant.

    Peptide
    Semaglutide
    Outcome
    IncreaseEligibility for renal transplantation
    Study

    n = 5

    Outcome group
    Body weight · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    who successfully achieved substantial weight loss using semaglutide, a glucagon-like peptide (GLP) type-1 receptor agonist, thereby becoming eligible for transplantation

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.